#Canada #Blainville #Biocodex #Médunik Canada #Diacomit®

Médunik Canada and Biocodex: A Strategic Partnership

In a significant development for pediatric neurology, Médunik Canada has entered into an exclusive promotional services agreement with Biocodex concerning the medication Diacomit®. This collaboration aims to bolster the support and treatment options available for Canadian families affected by Dravet syndrome, a rare and severe form of epilepsy.

Who are the Key Players?

Médunik Canada is a dedicated pharmaceutical company focused on enhancing the health and quality of life of individuals grappling with rare and debilitating diseases. Based in Blainville, Quebec, they are a part of the Duchesnay Pharmaceutical Group, which brings a wealth of experience in catering to niche medical needs.

Biocodex, a French biopharmaceutical company, is known for focusing on rare diseases and innovative therapies. The joining of forces between these two organizations is poised to create a robust support framework for healthcare professionals and patients alike.

The Details of the Agreement

Effective immediately, Médunik Canada will take charge of all sales, marketing, and medical affairs related to Diacomit® throughout Canada. This initiative is geared towards capitalizing on Médunik's specialized infrastructure aimed at rare diseases, enhancing their engagement with pediatric neurologists and epilepsy specialists nationwide.

Michael Gallo, Vice President of Regulatory and Medical Affairs at DPG, expressed enthusiasm about the collaboration, stating, “Dravet syndrome demands highly specialized care, and we are ready to deploy our field teams to assist specialists across the country.” He emphasized the commitment to maximizing therapeutic reach while prioritizing support and medical education tailored to practitioners' needs.

Understanding Dravet Syndrome

Dravet syndrome is a complex, lifelong neurological disorder characterized by frequent and often resistant seizures that typically present in infancy. The impact of the condition stretches beyond the patients themselves, often significantly affecting the lives of caregivers and families. Managing this disorder usually requires a dedicated team of specialized epilepsy care professionals.

Through their partnership, Médunik Canada and Biocodex aim to enhance educational outreach, ensuring that caregivers and healthcare providers have reliable access to information and support regarding this challenging condition. The agreement also aims to guarantee ongoing access to Diacomit® for eligible patients, thereby streamlining treatment pathways.

Looking Ahead

This alliance represents a shift in how Dravet syndrome is approached within the Canadian healthcare landscape. As Hubert Chapellier, Head of International Business at Biocodex Rare Diseases, observed, “Our collaborative efforts are set to empower patients and families in understanding this intricate disorder better.”

Both Médunik Canada and Biocodex are committed to advancing the knowledge surrounding Dravet syndrome, reinforcing their dedication to addressing the needs of the epilepsy community in Canada.

About Médunik Canada and Duchesnay Pharmaceutical Group

Founded in December 2009, Médunik Canada has a singular vision: to improve the quality of life for Canadians influenced by rare diseases. As part of Duchesnay Pharmaceutical Group, which boasts a robust portfolio of pharmaceutical companies, they are committed to providing therapies for rare diseases, thereby enhancing access to critical treatments.

For additional information about this partnership or Médunik Canada's initiatives, please visit Médunik Canada or follow their updates on LinkedIn.